Core Viewpoint - Eupraxia Pharmaceuticals Inc. (EPRX) shows potential for significant upside, with a mean price target of $11.1 indicating a 75.1% increase from its current price of $6.34 [1] Price Targets and Analyst Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $2.47, suggesting variability in analyst predictions. The lowest estimate is $6.58 (3.8% increase), while the highest is $14.00 (120.8% increase) [2] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about EPRX's earnings prospects, with a strong consensus on higher EPS estimates, which correlates with potential stock price increases [11] - Over the last 30 days, two EPS estimates have increased while one has decreased, leading to a 16.1% rise in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - EPRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] - While the consensus price target may not be a reliable measure of potential gains, it does provide a useful guide for price movement direction [14]

Core Insights - Eupraxia Pharmaceuticals announced positive 52-week follow-up data from its Phase 1b/2a RESOLVE trial for EP-104GI, a treatment for eosinophilic esophagitis (EoE), highlighting its potential as a once-a-year treatment option [1][2] Group 1: Trial Results - Cohorts 5 and 6 are the only groups to have reached 52 weeks in the RESOLVE trial, showing durable clinical symptom responses [3] - In Cohort 6, 2 out of 3 patients achieved clinical remission 52 weeks post-treatment, while 4 out of 6 patients from both Cohorts 5 and 6 remained in clinical remission [3] - At week 36, 67% of patients measured were in clinical remission, with no serious adverse events reported across over 200 patient-months of follow-up [3][4] Group 2: Symptom Improvement - In Cohort 6, patients experienced an average reduction in the Straumann Dysphagia Index (SDI) scores of -3.7, equating to a 58% improvement at week 52 [4] - Across Cohorts 5-7, the average reduction in SDI scores was -3.0, or 53%, at week 36, while 79% of patients in Cohorts 4-8 were in clinical remission at week 24 [4] Group 3: Pharmacokinetics - Plasma levels of fluticasone in Cohort 6 remained stable and predictable over 52 weeks, significantly lower than levels typically seen with daily asthma inhalers [4] - No serious adverse events or cases of oral or gastrointestinal candidiasis were reported during the trial [4] Group 4: Future Developments - The Phase 2b part of the RESOLVE trial is currently recruiting participants, with top-line data expected in Q3 2026 [8] - Eupraxia plans to disclose additional data from the ongoing RESOLVE trial in the coming months [7]

Core Insights - Eupraxia Pharmaceuticals reported durable symptom and tissue responses for EP-104GI, with data observed up to 52 weeks following a single treatment, indicating its potential as an effective treatment for eosinophilic esophagitis (EoE) [1][2] - The company completed a public offering raising $80.5 million, which will support the advancement of the EP-104GI program and other pipeline developments [4][2] - The company has sufficient cash reserves to fund operations and pipeline development into the first half of 2028, with cash on hand reported at $89.0 million as of September 30, 2025 [6][7] Clinical Trial Updates - The Phase 1b/2a RESOLVE Trial showed that two-thirds of patients in Cohort 5 remained in clinical remission after treatment with EP-104GI, demonstrating long-term disease control [3] - The highest-dose cohort in the RESOLVE trial exhibited the largest improvements in tissue health outcomes and eosinophil reduction, with no additional safety concerns reported [2] Financial Performance - For Q3 2025, the company incurred a net loss of $6.4 million, slightly higher than the $6.0 million loss in Q3 2024, primarily due to increased research and development costs [5] - The company’s cash position improved significantly from $33.1 million at the end of Q4 2024 to $89.0 million as of September 30, 2025, allowing for continued funding of clinical trials and operational needs [6] Market and Operational Considerations - The company is monitoring the potential impacts of proposed tariffs on Canadian goods by the U.S. government and retaliatory tariffs by Canada, which could affect its operations [8][10] - Eupraxia manufactures its clinical supplies in the U.S. and maintains U.S. dollar balances to mitigate the impact of exchange rate fluctuations [9]

Exhibit 99.1 EUPRAXIA PHARMACEUTICALS INC. CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months ended September 30, 2025 (Unaudited and Expressed in U.S. Dollars) EUPRAXIA PHARMACEUTICALS INC. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS September 30, 2025 (Unaudited and Expressed in U.S. Dollars) CONTENTS | CONSOLIDATED BALANCE SHEETS | 2 | | --- | --- | | CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | 3 | | CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY | 4-6 | | CONSOLIDATED STA ...

Core Viewpoint - Eupraxia Pharmaceuticals Inc. (EPRX) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Ratings - The Zacks rating system is based solely on a company's changing earnings picture, tracking the Zacks Consensus Estimate for EPS from sell-side analysts [2]. - The recent upgrade reflects an improvement in Eupraxia's earnings outlook, which is expected to lead to increased buying pressure and a rise in stock price [4][6]. Impact of Earnings Estimate Revisions - There is a strong correlation between changes in earnings estimates and near-term stock price movements, making the Zacks rating system valuable for investors [5][7]. - Eupraxia's earnings estimates have been revised upward, with a 7.6% increase in the Zacks Consensus Estimate over the past three months [9]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [8]. - Eupraxia's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating strong potential for market-beating returns in the near term [10][11].

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Eupraxia Pharmaceuticals Inc. (EPRX) - EPRX currently holds a Momentum Style Score of B and a Zacks Rank of 2 (Buy), indicating strong potential for outperformance [3][4] - The stock has shown significant price appreciation, with a 16.57% increase over the past quarter and a remarkable 156.36% rise over the last year, compared to the S&P 500's 6.67% and 15.74% respectively [7] Price Performance - EPRX shares increased by 3.76% over the past week, while the Zacks Medical - Biomedical and Genetics industry declined by 0.34% during the same period [6] - The monthly price change for EPRX is 14.15%, outperforming the industry average of 6.95% [6] Trading Volume - The average 20-day trading volume for EPRX is 210,498 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - Over the past two months, two earnings estimates for EPRX have been revised upwards, with the consensus estimate improving from -$0.80 to -$0.73 [10] - For the next fiscal year, two estimates have also moved higher, with no downward revisions noted [10] Conclusion - Given the positive momentum indicators and earnings outlook, EPRX is positioned as a strong buy candidate for investors seeking growth opportunities [12]

Core Viewpoint - Eupraxia Pharmaceuticals Inc. (EPRX) has shown a significant price increase of 14.2% over the past four weeks, with a mean price target of $11.2 indicating an upside potential of 85.1% from the current price of $6.05 [1] Price Targets and Estimates - The mean estimate consists of five short-term price targets with a standard deviation of $1.3, where the lowest estimate is $9.00 (48.8% increase) and the highest is $12.00 (98.4% increase) [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement [9] Analyst Sentiment and Earnings Estimates - Analysts have shown increasing optimism about EPRX's earnings prospects, as indicated by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 8.4%, with two estimates moving higher and no negative revisions [12] Zacks Rank and Investment Potential - EPRX currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] - While consensus price targets may not be entirely reliable, the implied direction of price movement appears to be a useful guide for potential investment [14]

Core Insights - Eupraxia Pharmaceuticals Inc. has provided an operational update on the development of EP-104GI, reporting data from Cohort 9 of the RESOLVE trial, where patients received an 8mg dose per injection for the first time [1][2] Clinical Trial Results - Cohort 9 demonstrated the largest improvements in tissue health outcomes and eosinophil reduction to date, with no serious adverse events reported [5][6] - The RESOLVE Safety Committee endorsed the 8mg dose as the second dose for the ongoing Phase 2b study, indicating strong confidence in the dosing strategy [5][6] - The company plans to expand the Phase 2b study from 60 to at least 120 patients, enhancing the statistical power and safety database [8][13] Future Plans - Eupraxia intends to initiate a clinical trial for an additional gastrointestinal indication in the first half of 2026, leveraging recent financing to support this expansion [5][8] - The company aims to disclose additional data from the RESOLVE trial in Q4 2025 and expects top-line data from the Phase 2b trial in Q3 2026 [9][16] Technology and Market Potential - EP-104GI utilizes Eupraxia's proprietary Diffusphere™ technology for localized drug delivery, which may improve safety and efficacy compared to traditional methods [15][16] - Eosinophilic Esophagitis (EoE) affects over 450,000 people in the U.S., indicating a significant market opportunity for effective treatments [11][16]

Core Viewpoint - Eupraxia Pharmaceuticals has successfully closed a public offering of 14,636,363 common shares at a price of US$5.50 per share, raising approximately US$80.5 million in gross proceeds, which will be used to advance its product pipeline and support key clinical and regulatory milestones [1][2][3] Group 1: Offering Details - The public offering included the full exercise of the underwriters' option to purchase additional shares [1] - The offering was conducted under a U.S. registration statement declared effective by the SEC and the existing Canadian short form base shelf prospectus [4] Group 2: Use of Proceeds - The net proceeds from the offering will primarily fund the advancement of the product pipeline, including ongoing preclinical studies, clinical trials, regulatory submissions, and commercial preparation [3] - Additional allocations will support research and development of new pipeline candidates, business development initiatives, and general corporate purposes [3] Group 3: Company Background - Eupraxia Pharmaceuticals is a clinical-stage biotechnology company focused on developing locally delivered, extended-release products to address high unmet medical needs [7] - The company utilizes its proprietary Diffusphere™ technology for optimized local drug delivery [7]

Core Viewpoint - Eupraxia Pharmaceuticals has priced its public offering of 12.7 million shares at $5.50 per share, raising approximately $70 million to advance its product pipeline and related commercial activities [1] Summary by Category - **Company Actions** - Eupraxia Pharmaceuticals is conducting a public offering of 12.7 million shares [1] - The offering price is set at $5.50 per share [1] - **Financial Implications** - The company aims to raise about $70 million through this offering [1] - **Use of Proceeds** - Funds raised will be utilized to advance the company's product pipeline and related commercial activities [1]